Dishman Carbogen, a company in the Pharmaceuticals industry, reported revenue of ₹507 crore and a net loss of ₹67 crore for the September 2026 quarter.
Dishman Carbogen (NSE: DCAL) closed at ₹115.57 on 20 Nov 2026, down 53.0% over the past year. Its market capitalisation is ₹1,812 crore.
Dishman Carbogen Amcis Ltd is engaged in Contract Research and Manufacturing Services (CRAMS) and manufacture and supply of marketable molecules such as specialty chemicals, vitamins & chemicals and disinfectants with presence in Switzerland, UK, Europe, China and other countries.
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.